Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs

Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs

Cytochrome P450 2D6 (CYP2D6) activity is highly variable due to several factors, including genetic polymorphisms and drug-drug-gene interactions. Hydrocodone, oxycodone, codeine, and tramadol the most commonly prescribed CYP2D6-activated opioids for pain. However, the co-administration of CYP2D6 int...

Full description

Bibliographic Details
Main Authors:	Veronique Michaud, Ravil Bikmetov, Matt K. Smith, Pamela Dow, Lucy I. Darakjian, Malavika Deodhar, Brian Cicali, Kevin T. Bain, Jacques Turgeon
Format:	Article
Language:	English
Published:	MDPI AG 2021-11-01
Series:	Journal of Personalized Medicine
Subjects:	CYP2D6 drug-drug interactions opioids medical expenditure pharmacoeconomics medication risk score
Online Access:	https://www.mdpi.com/2075-4426/11/11/1174

Similar Items

Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition
by: Malavika Deodhar, et al.
Published: (2021-01-01)

Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
by: Malavika Deodhar, et al.
Published: (2020-09-01)

Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy
by: Sweilem B. Al Rihani, et al.
Published: (2020-08-01)

Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level
by: Sweilem B. Al Rihani, et al.
Published: (2021-04-01)

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism
by: Malavika Deodhar, et al.
Published: (2021-09-01)

Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly
by: David L. Bankes, et al.
Published: (2020-05-01)

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice
by: Qamar Shubbar, et al.
Published: (2024-02-01)

Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
by: Florian Klomp, et al.
Published: (2020-12-01)

Age-related modifications in CYP-dependent drug metabolism: role of stress
by: Maria Konstandi, et al.
Published: (2023-05-01)

CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation
by: A. A. Kurylev, et al.
Published: (2018-05-01)

Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions
by: Rosemary T. Smith, et al.
Published: (2023-01-01)

Outcomes research and drug development
by: Sandeep Duttagupta
Published: (2010-01-01)

Classification and Assessment of Medication Risk in the Elderly (CARE): Use of a Medication Risk Score to Inform Patients’ Readmission Likelihood after Hospital Discharge
by: Savanna SanFilippo, et al.
Published: (2021-08-01)

Drugs with the highest drug expenditure in the Republic of Serbia
by: Milijašević Boris Ž., et al.
Published: (2023-01-01)

Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia
by: V. G. Deriushkin, et al.
Published: (2021-02-01)

Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators
by: Lien Thi Ngo, et al.
Published: (2023-01-01)

CHANGES IN THE COSTS OF HYPERTENSIVE CRISIS THERAPY DUE TO OPTIMIZATION OF DRUG SUPPLY IN THE PRE-ADMISSION CARE
by: N. I. Gaponova, et al.
Published: (2015-12-01)

Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2/3A4 and BCRP/P-gp
by: Tingting Zhao, et al.
Published: (2022-08-01)

THE CHOICE OF THE DRUG AMLODIPINE FOR THE HYPERTENSION TREATMENT FROM THE STANDPOINT OF ECONOMIC FEASIBILITY
by: S. Yu. Martsevich, et al.
Published: (2016-01-01)

The concept of: Generic drugs and patented drugs Vs brand name drugs and non-proprietary (generic) name drugs.
by: Karan eThakkar, et al.
Published: (2013-09-01)

Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo
by: Shan Zhou, et al.
Published: (2023-12-01)

Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for Vancomycin in Elderly Patients
by: Yun Kim, et al.
Published: (2022-01-01)

Hyponatremic Cognitive Dysfunction Resulting from Drug-Drug-Gene Interaction between Sertraline and Cannabidiol in an Intermediate CYP2C19 Metabolizer Patient
by: Jade Nanan, et al.
Published: (2022-09-01)

Phenotyping Indices of CYP450 and P-Glycoprotein in Human Volunteers and in Patients Treated with Painkillers or Psychotropic Drugs
by: Léa Darnaud, et al.
Published: (2023-03-01)

Opioids, Polypharmacy, and Drug Interactions: A Technological Paradigm Shift Is Needed to Ameliorate the Ongoing Opioid Epidemic
by: Adriana Matos, et al.
Published: (2020-08-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

Assessment of Substrate Status of Drugs Metabolized by Polymorphic Cytochrome P450 (CYP) 2 Enzymes: An Analysis of a Large-Scale Dataset
by: Jakob Sommer, et al.
Published: (2024-01-01)

Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity
by: Lucy Darakjian, et al.
Published: (2021-05-01)

Outpatient antihypertensive drug utilization in Canton Sarajevo during five years period (2004-2008) and adherence to treatment guidelines assessment
by: Tarik Čatić, et al.
Published: (2011-05-01)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
by: David Damoiseaux, et al.
Published: (2022-07-01)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
by: Ping Siu Kee, et al.
Published: (2023-02-01)

Case report: Medical cannabis—warfarin drug-drug interaction
by: Tyan F. Thomas, et al.
Published: (2022-01-01)

Drug-drug interactions of tacrolimus
by: Rančić Nemanja K., et al.
Published: (2015-01-01)

Drugs and society : a biological perspective /
by: 215866 Witters, Patricia Jones, et al.
Published: (1983)

Nanoparticulate Drug Delivery Strategies to Address Intestinal Cytochrome P450 CYP3A4 Metabolism towards Personalized Medicine
by: Rui Xue Zhang, et al.
Published: (2021-08-01)

ABC Transporters and CYP3A4 Mediate Drug Interactions between Enrofloxacin and Salinomycin Leading to Increased Risk of Drug Residues and Resistance
by: Min Chen, et al.
Published: (2023-02-01)

Optimising Seniors’ Metabolism of Medications and Avoiding Adverse Drug Events Using Data on How Metabolism by Their P450 Enzymes Varies with Ancestry and Drug–Drug and Drug–Drug–Gene Interactions
by: Roger E. Thomas
Published: (2020-08-01)

Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict CYP3A-Mediated Drug Interaction between Saxagliptin and Nicardipine: Bridging Rat-to-Human Extrapolation
by: Jeong-Min Lee, et al.
Published: (2024-02-01)

Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis
by: Cui Li, et al.
Published: (2024-01-01)

Interaction Potential of the Multitargeted Receptor Tyrosine Kinase Inhibitor Dovitinib with Drug Transporters and Drug Metabolising Enzymes Assessed in Vitro
by: Johanna Weiss, et al.
Published: (2014-12-01)